Ready-to-Use Liquid NivobotulinumtoxinA Treats Frown Lines Safely and Effectively
Two randomized double-blind placebo-controlled Phase III clinical trials tested a new ready-to-use liquid form of nivobotulinumtoxinA for treating moderate-to-severe frown lines (glabellar lines), both on its own and alongside crow’s feet. By 30 days after injection, a notably higher number of patients who received the treatment showed clear improvements — with many achieving “none or mild” wrinkle visibility — compared to zero improvement in the placebo group. The results were statistically significant (all comparisons were P < .001). Importantly, the treatment was well-tolerated, with adverse event rates similar to placebo. These findings suggest that this liquid form of nivobotulinumtoxinA is effective and well tolerated for treating moderate-to-severe frown lines alone or with crow’s feet lines.
Disclaimer: NivobotulinumtoxinA is an investigational drug and is not yet approved by US FDA or HealthCanada.
Clinical trials confirm significant improvement in crow’s feet with a well-tolerated, ready-to-use treatment.
In two other randomized double-blind placebo-controlled clinical trials, patients who received the treatment showed significantly smoother skin compared to placebo, with many reaching “none or mild” wrinkle ratings by day 30. The product was well-tolerated, with only mild side effects such as headache, and no unexpected safety concerns. These results suggest nivobotulinumtoxinA is effective and well tolerated for treating moderate-to-severe crow’s feet with or without frown lines.
Disclaimer: NivobotulinumtoxinA is an investigational drug and is not yet approved by US FDA or HealthCanada.
